Hepion Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Hepion Pharmaceuticals

16/04/2024 23:15

* Hepion Pharmaceuticals Inc  HEPA.OQ  reported a quarterly
adjusted loss of $2.42​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-2.60.  The mean expectation of
two analysts for the quarter was for a loss of $2.63 per share. 
    * Reported revenue was zero​. 
    * Hepion Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $2.42​.
    * The company reported a quarterly loss of $11.06 million.
    * Hepion Pharmaceuticals Inc shares had fallen by 12.4% this
quarter and lost 32.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Hepion
Pharmaceuticals Inc is $26.00 

This summary was machine generated from LSEG data April 16 at
10:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -2.63          -2.42          Beat
 Sep. 30 2023      -3.12          -2.74          Beat
 Jun. 30 2023      -3.32          -3.68          Missed
 Mar. 31 2023      -3.60          -3.48          Beat